Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 9.70% is 15% above its 5-year average of 8.44%, near the high end of its 5-year range (7.01%–9.71%).
As of the fiscal period ended Friday, April 24, 2026. 0.05% below its 12-month average of 9.71%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
9.70%
RETURN ON EQUITY (ROE) AVG TTM
9.71%
RETURN ON EQUITY (ROE) AVG 3Y
8.51%
RETURN ON EQUITY (ROE) AVG 5Y
8.44%
RETURN ON EQUITY (ROE) AVG 10Y
8.21%
RETURN ON EQUITY (ROE) AVG 15Y
8.54%
RETURN ON EQUITY (ROE) AVG 20Y
13.34%
CURRENT VS TTM AVG
-0.05%
CURRENT VS 3Y AVG
+14.02%
CURRENT VS 5Y AVG
+14.95%
CURRENT VS 10Y AVG
+18.19%
CURRENT VS 15Y AVG
+13.53%
CURRENT VS 20Y AVG
-27.31%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-10.93%
vs the sector median at left
Medtronic plc
Market Cap
$109.30B
Return on Equity (ROE)
9.70%
TTM Avg
9.71%
3Y Avg
8.51%
5Y Avg
8.44%
Market Cap
$100.24B
Return on Equity (ROE)
-219.24%
TTM Avg
-189.06%
3Y Avg
-180.53%
5Y Avg
3473.86%
Market Cap
$121.09B
Return on Equity (ROE)
22.41%
TTM Avg
8.96%
3Y Avg
15.60%
5Y Avg
19.47%
Market Cap
$124.82B
Return on Equity (ROE)
17.28%
TTM Avg
15.07%
3Y Avg
13.91%
5Y Avg
13.46%
Market Cap
$124.86B
Return on Equity (ROE)
7.78%
TTM Avg
14.50%
3Y Avg
15.05%
5Y Avg
14.30%
Market Cap
$87.16B
Return on Equity (ROE)
-112.56%
TTM Avg
-171.53%
3Y Avg
-210.62%
5Y Avg
-155.29%
Market Cap
$131.47B
Return on Equity (ROE)
21.95%
TTM Avg
19.16%
3Y Avg
15.60%
5Y Avg
13.86%
Market Cap
$133.25B
Return on Equity (ROE)
3.79%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medtronic plc (MDT) | $109.30B | 9.70% | 9.71% | 8.51% | 8.44% |
| GSK plc (GSK)vs › | $103.56B | 25.19% | 26.90% | 55.97% | 45.70% |
| McKesson Corporation (MCK)vs › | $100.24B | -219.24% | -189.06% | -180.53% | 3473.86% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $121.09B | 22.41% | 8.96% | 15.60% | 19.47% |
| Intuitive Surgical, Inc. (ISRG)vs › | $124.82B | 17.28% | 15.07% | 13.91% | 13.46% |
| Stryker Corporation (SYK)vs › | $124.86B | 7.78% | 14.50% | 15.05% | 14.30% |
| HCA Healthcare, Inc. (HCA)vs › | $87.16B | -112.56% | -171.53% | -210.62% | -155.29% |
| AstraZeneca PLC (AZN)vs › | $131.47B | 21.95% | 19.16% | 15.60% | 13.86% |
| CVS Health Corp. (CVS)vs › | $133.25B | 3.79% | 4.23% | 6.35% | 7.74% |
| Bristol-Myers Squibb Company (BMY)vs › | $133.37B | 41.59% | -8.30% | 7.76% | 4.45% |
ROE
9.7%
ROA
5.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-04-24 | 9.70% |
| 2025-04-25 | 9.71% |
| 2024-04-26 | 7.32% |
| 2023-04-28 | 7.30% |
| 2022-04-29 | 9.59% |
| 2021-04-30 | 7.01% |
| 2020-04-24 | 9.44% |
| 2019-04-30 | 9.25% |
| 2018-04-30 | 6.12% |
| 2017-04-30 | 8.01% |
| 2016-04-30 | 6.83% |
| 2015-04-30 | 5.03% |
| 2014-04-30 | 15.76% |
| 2013-04-30 | 18.57% |
| 2012-04-30 | 21.14% |
| 2011-04-30 | 19.39% |
| 2010-04-30 | 21.18% |
| 2009-04-30 | 16.88% |
| 2008-04-30 | 19.34% |
| 2007-04-30 | 25.53% |
| 2006-04-30 | 27.14% |
| 2005-04-30 | 17.26% |
| 2004-04-30 | 21.59% |
| 2003-04-30 | 20.23% |
| 2002-04-30 | 15.30% |
| 2001-04-30 | 18.99% |
| 2000-04-30 | 24.46% |
| 1999-04-30 | 12.42% |
| 1998-04-30 | 29.09% |
| 1997-04-30 | 33.40% |
